To me this looks good, but I wonder what the market will make of this: “An uneven profit profile for CSL is expected for the first and second half results, due to the seasonality of the influenza business and the timing of expenses – particularly research and development,” Mr. Perreault added.
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$253.18 |
Change
4.790(1.93%) |
Mkt cap ! $120.2B | |||
| Open | High | Low | Value | Volume |
| $252.00 | $253.64 | $251.10 | $174.5M | 675.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9 | $253.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $253.15 | 22 | 2 |
View Market Depth
| Last trade - 10.30am 18/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |